Loss-of-function mutations in the phosphatase PTEN (phosphatase and tensin homolog deleted on chromosome10) contribute to aberrant cell growth in part through upregulation of the mitogenic IGF-1/PI 3 K/Akt pathway. In turn, this pathway exerts a homeostatic feedback over PTEN. Using mutagenesis analysis to explore a possible impact of this mutual control on astrocyte growth, we found that truncation of the C-terminal region of PTEN (D51) associates with a marked increase in NFkB activity, a transcription factor overactivated in astrocyte tumors. Whereas mutations of PTEN are considered to lead to a loss-of-function, PTEND51, a truncation that comprises a region frequently mutated in human gliomas, displayed a neomorphic (gain-of-function) activity that was independent of its phosphatase activity. This gain-of-function of PTEND51 includes stimulation of IGF-1 synthesis through protein kinase A activation of the IGF-1 promoter. Increased IGF-1 originates an autocrine loop that activates Akt and NFkB. Constitutive activation of NFkB in PTEND51-expressing astrocytes leads to aberrant cell growth; astrocytes expressing this mutant PTEN generate colonies in vitro and tumors in vivo. Mutations converting a tumor suppressor such as PTEN into a tumor promoter through a gain-of-function involving IGF-1 production may further our understanding of the role played by this growth factor in glioma growth and help us define druggable targets for personalized therapy.
INTRODUCTION

Dysregulation of a receptor tyrosine kinase (RTK)/phosphatidylinositol 3
0 -kinase (PI 3 K)/Akt pathway is one of the three core pathways for glioblastoma formation, 1 the most frequent type of brain tumor. 2 Genetic alteration of PTEN abrogates its tumor suppressor role as this phosphatase counterbalances the PI 3 K/Akt pathway. 3 Although the most common RTK mutation in gliomas affects the EGF receptor, insulin growth factor-I (IGF-1) and its receptor may act as oncogenes in different tumors through the PI 3 K pathway. 4 Indeed, both IGF-1 and its receptor are highly abundant in human gliomas. 5, 6 However, the role of IGF-1/IGF-1R in glioma biology is not fully understood.
A few years ago, we reported that IGF-1 inhibits the transcription factor nuclear factor kB (NFkB) in astrocytes undergoing inflammatory activation, 7 whereas more recently we found that IGF-1 participates in a homeostatic feedback of PTEN expression through PI 3 K in normal astrocytes. 8 NFkB is constitutively active in many tumors 9 including gliomas. 10 This transcription factor induces the expression of numerous genes involved in cell survival, proliferation, angiogenesis, invasion and metastasis 11 and is a canonical activator of inflammatory routes. 12 This latter aspect links inflammatory signaling with cancer.
11
Mechanisms underlying NFkB activation in cancer are becoming apparent. 13 While analyzing a possible impact of the above mentioned interactions between PTEN, IGF-1 and NFkB on astrocyte growth, we unveiled a novel gain-of-function of a PTEN mutation frequently detected in gliomas. 1 Truncation of the C-terminal region of PTEN (PTEND51) turns this tumor suppressor phosphatase into a tumor promoter by establishing an autocrine IGF-1 loop that leads to constitutive NFkB activation. Astrocytes expressing PTEND51 display aberrant growth in vitro and in vivo.
RESULTS
PTEN inhibits NFkB activity in astrocytes independently of its phosphatase activity
We analyzed whether NFkB is inhibited by PTEN in astrocytes, as this phosphatase inhibits this transcription factor in other cell types. 14, 15 As shown in Figure 1a , overexpression of PTEN inhibited basal and TNFa-stimulated NFkB activity in astrocytes expressing an NFkB gene reporter. The degree of inhibition was similar to that observed with IGF-1, a previously established inhibitor of NFkB in astrocytes. 7 Downstream of NFkB activation, there are proteins such as cyclo-oxygenase 2 (Cox2) or inducible nitric oxide synthase (iNOS) that are used as tumor prognosis markers in glioma. 16 Both basal and TNFa-stimulated levels of these two proteins were inhibited by overexpression of PTEN (Figure 1b) . We then determined whether the phosphatase activity of PTEN is involved in inhibition of NFkB as the phosphatase activity of PTEN may be involved in its antitumoral effects. 17 A PTEN mutant lacking lipid phosphatase activity (C129E, Figure 1c ) or a mutant without lipid and protein phosphatase activities (G124E; Figure 1c ) abrogated basal and TNFa-stimulated NFkB activity or downstream proteins such as Cox2 and iNOS, similarly to wildtype (wt) PTEN (Figure 1d and e). This indicates that the phosphatase activity of PTEN is not required for inhibition of NFkB, which agrees with previous reports of phosphataseindependent actions of PTEN. 18 Truncated PTEN stimulates NFkB To determine the region of PTEN involved in inhibition of NFkB, we generated different truncated forms of PTEN and transfected them to astrocytes expressing the NFkB reporter. Depending on the region eliminated, mutants displayed full inhibition of NFkB (not shown), no inhibition (not shown) or stimulation. Because the latter effect was unexpected we further analyzed it. Specifically, elimination of the C-terminal region of PTEN comprising residues 352-403 (PTEND51, Figure 1c ) conferred the ability to enhance basal and TNFa-stimulated activity (Figure 2a) . Truncation of the C-terminal region of PTEN (residues 300-403) is frequently found in human gliomas 1 and other human cancers (Table 1 19,20 ) Significantly, over a twofold increase in cell proliferation was observed in astrocytes transiently expressing PTEND51 (Po0.001 vs GFP-transfected astrocytes). Similar results were observed when a PTEND51Stop protein without GFP was used, indicating that the GFP moiety is not involved (not shown). When astrocytes were stably transfected with PTEND51, they proliferated significantly faster as compared with GFP-transfected astrocytes (Figure 2b ). Because astrocyte proliferation induced by PTEND51 was abolished by QNZ (Figure 2c ), an NFkB inhibitor (Figure 2d ) that interferes with basal cell proliferation (Figure 2c ), it seems that PTEND51 hijacks this transcription factor involved in normal cell growth.
Pathways linking expression of PTEND51 with NFkB activity We determined pathways involved in PTEND51-induced stimulation of NFkB activity. PTEND51 activated the canonical AKT/IkBa pathway, as both kinases were phosphorylated in its presence in a similar way as after TNFa, a known activator of this pathway (Figure 3a) . Further, stimulation by PTEND51 of basal or TNFaactivated NFkB was abolished by the PI 3 K inhibitor LY294002 or by a dominant negative (kinase dead) Akt (Figure 3b ). Pharmacological screening of pathways upstream of Akt revealed that PKA activity was involved. The PKA inhibitor H89 abrogated PTEND51-induced phosphorylation of Akt (Figure 3c ) whereas forskolin, a PKA activator, mimicked PTEND51 effects on Akt phosphorylation (Figure 3c ). Further, LY294002 abolished PTEND51-induced Akt phosphorylation (Figure 3c ). In accordance with the pharmacological data, expression of a dominant-negative PKA (PKA-M) abolished increased Akt phosphorylation (Figure 3d ), NFkB activity ( Figure 3e ) and cell proliferation (Figure 3f ) induced by PTEND51. Furthermore, whereas wt PTEN did not affect PKA activity, PTEND51 significantly stimulated it ( Figure 3f ).
As PTEND51 maintains its lipid phosphatase activity (Supplementary Figure 1a) , we wanted to know if PTEND51 gain-of-function depends on it. We found that PTEND51 mutants lacking phosphatase activity (Supplementary Figure 1b retain their ability to stimulate NFkB and cell proliferation ( Supplementary Figure 1c and d) . Because in wild-type astrocytes endogenous PTEN is still present after transfection with PTEND51, we eliminated it to rule out a possible interference with PTEND51. Indeed, wt PTEN antagonized the activity of PTEND51. Depletion of wt PTEN in PTEN loxP/loxP astrocytes by transfection of Crerecombinase exacerbated PTEND51 effect on NFkB activation through Akt and IkBa phosphorylation (Figures 4a-c) . Conversely, coexpression of PTEND51 with the C-terminal region of PTEN (PTEN353-403) to reconstitute full PTEN activity 21 antagonized its effects. Both NFkB and cell proliferation were no longer stimulated by PTEND51 in the presence of PTEN Tail (PTEN353-403) ( Figures  4c and d ).
An autocrine IGF-1 loop is involved in PTEND51 gain-of-function As already discussed, IGF-1 promotes cell growth and therefore restraining its signaling forms part of the tumor suppressor role of PTEN. In turn IGF-1 participates in the homeostasis of PTEN through PI 3 K as both enzymes regulate each other. 22 Because PKA stimulates the synthesis of IGF-1 in other cell types, 23, 24 we hypothesized that PTEND51 might recruit IGF-1 to promote aberrant astrocyte growth as part of its neomorphic activity. We cotransfected astrocytes with an IGF-1 transcription reporter 25 and PTEND51. More than a threefold increase in IGF-1 transcription was observed when PTEND51 was expressed ( Figure 5a ). This increase was abolished when astrocytes were incubated with H89, when expressed a dominant-negative PKA or when the IGF-1 reporter lacked a PKA response element (pDIGF-1-Luc; Figure 5a PTEND51 induces p53 phosphorylation and aberrant cell proliferation p53 is a key tumor suppressor protein regulated by kinases 26 that is phosphorylated during the DNA damage response (DDR), a process associated with aberrant cell proliferation. 27 Phosphorylation of p53 is promoted by IGF-1 in cancer cells, 28 whereas p53 activity is also modulated by constitutive activation of NFkB. 29 In face of increased IGF-1 levels and constitutive NFkB activation in PTEND51-expressing astrocytes, we determined whether phosphorylation of p53 was affected. Indeed, we found Gain-of-function of PTEN in glioma S Fernández et al increased phosphorylation of p53 in the presence of PTEND51, whereas total levels of p53 were slightly decreased ( Figure 6a ). Because increased production of reactive oxygen species (ROS) is found in human tumors 30 and ROS modulate p53 activity, 31 we also looked for possible changes in ROS levels in PTEND51-expressing astrocytes and found them increased (Figure 6b) . Finally, to determine whether PTEND51 induces malignant transformation, we stably transfected astrocytes with PTEND51 and check their ability to form colonies in vitro. Four weeks after plating, astrocytes were fixed and stained with crystal violet. PTEND51-expressing astrocytes grew forming foci, which is a characteristic feature of transformed cells, whereas astrocytes expressing GFP did not show foci formation (Figure 6c) . Furthermore, subcutaneous injection in nude SCID mice of astrocytes stably expressing PTEND51 originated tumors that grew significantly faster and larger than astrocytes expressing GFP (Figure 6d ).
DISCUSSION
The present findings indicate that an alternative path to upregulated PI3K/Akt activity, a common finding in gliomas, 1 is through a gain-of-function of PTEN when its C-tail is deleted. Truncation of the C-tail of PTEN is frequent in gliomas 1 and may underlie tumor onset in these cases. Allelic or complete deletion of PTEN is also frequently observed in prostate and breast cancers as well as in melanoma and glioma (see the Tumorscape website). From a total of 68% of PTEN deletions found in tumor samples, more than half (55%) of them are due to a deletion in the C-terminal region (from residues 300-403 19, 20 ). The neomorphic activity of truncated PTEN involves activation of PKA, a kinase that is not activated by wt PTEN. In turn, PKA stimulates the synthesis of IGF-1, which activates Akt and NFkB through an autocrine loop.
As a result, astrocytes develop an aberrant growth phenotype that may in turn trigger a defensive response through p53 phosphorylation. Indeed, increased p53 phosphorylation indicates oncogenic stress, an initial oncogenic signal in early tumorigenesis. 32 As the p53 pathway activates cell senescence and cell cycle arrest, 26 increased proliferation in astrocytesexpressing PTEND51 together with increased p53 phosphorylation could reflect two parallel events: proliferation mediated by IGF-1 and response to oncogenic stress mediated by p53. However, given the complexity of p53 regulation and its impact in cancer, 33 it is difficult to determine the true significance of phosphorylated p53 in this context. Additional experiments are needed to clarify this point.
Although loss of wt PTEN in astrocytes is not sufficient to generate aberrant cell proliferation, 34 our results indicate that C-tail truncation of PTEN comprising residues 353-403 is sufficient to generate a malignant phenotype even without PTEN loss, as PTEND51 is active in the presence of wt PTEN. Although more work is warranted, this observation arises the possibility that astrocytes are the cell of origin for certain types of gliomas (see Chen et al. 10 ). Thus, as seen with other tumor suppressor proteins, PTEN can be turned into a tumor promoter. Neomorphic activities have already been reported for other genes frequently mutated in gliomas such as IDH1/2. 35 The tumor suppressor function of PTEN may depend on its lipid phosphatase activity that counteracts PI 3 K activity by dephosphorylation. 17 However, different studies propose tumor suppressor functions of PTEN that are independent of its phosphatase activity. [36] [37] [38] The neomorphic activity of mutated PTEN described herein conforms to this idea as it is phosphatase independent. PTEN possesses several functional domains: a N-PIP 2 binding domain, the phosphatase domain, a C2 domain and a C-terminal regulatory domain. 36 The C-tail (aa 353-403) regulates its stability, degradation and cellular localization through intramolecular interaction with the C2 domain. 39 Of the monoallelic mutations in PTEN found in gliomas, 40 32% leads to premature truncation of the protein in exons 8 or 9 41, 42 resulting in loss of the C-tail. Such mutations do not eliminate the enzymatic activity of PTEN, but decrease its cellular half life because of rapid degradation. 43 Little is known about other characteristics of these mutants, but interactions with other proteins may be enhanced 44 and intramolecular interactions known to regulate PTEN activity may be ablated or distorted. 21 The latter agrees with the rescuing action of coexpression of the C-terminal region of PTEN (PTEN353-403) to reconstitute full PTEN activity (Figures 5c  and d) . De novo interactions with other proteins may explain the activation of PKA by PTEND51, but more work is needed to determine the underlying mechanism.
Protein kinase A has been shown to either inhibit glioma growth 45 or stimulate PTEN expression in astrocytes 8 or, conversely, to participate in activation of NFkB in different cancer types or decrease PTEN activity. 46 In this case, the neomorphic activity of mutated PTEN appears to recruit PKA to activate the IGF-1 promoter, a known target of this kinase. 24 In turn, IGF-1 levels are elevated in gliomas, 47, 48 and blockade of IGF-1 signaling has been implemented as a therapy for gliomas. 49 Although IGF-1 was shown by us to inhibit NFkB activity after proinflammatory challenge in astrocytes independently of PI 3 K/Akt, 7 this transcription factor is stimulated by PI 3 K/Akt through IkBa 50 in tumor cells. As the action of IGF-1 is cell-context dependent, 51 it may well be that Akt stimulation by IGF-1 under pro-tumorigenic conditions, such as elevated ROS levels, that enhance Akt sensitivity to IGF-1 (unpublished observations) will result in an opposite effect on NFkB activity.
In summary, a neomorphic activity of a frequently found mutation of PTEN in human gliomas generates aberrant cell growth in primary astrocytes, even in the presence of wt PTEN, by recruiting through PKA an autocrine IGF-1 loop that generates a constitutive NFkB activity. Because treatment of gliomas is ineffective at present, understanding underlying molecular pathways may lead to personalized effective treatments. Thus, in the subpopulation of patients bearing this type of C-terminal mutations in PTEN, the use of PKA inhibitors may be beneficial.
MATERIALS AND METHODS Materials
Culture media, serum and supplements were from Invitrogen (Carlsbad, CA, USA). Human recombinant IGF-I (PreProtec, London, UK) was dissolved in 0. from BIOMOL (Enzo LIfe Sciencies, Farmingdale, NY, USA). NVP-AEW541 was from Cayman Chemical and Forskolin was from Sigma .
Plasmids and reporter constructs PTEN-GFP and PTENC124S-GFP were kindly provided by Dr F. SanchezMadrid, (Spain). The PTENG129E-GFP, PTEND51-GFP, PTEND216-GFP, PTENATG177-352-GFP, PTENATG177-403-GFP, PTEN TAIL ATG353-403-GFP, PTEN D51G129EGFP and PTEN D51C124SGFP were generated by PCR amplification and cloned in-frame fused to GFP green fluorescence protein in peGFP-N1 (Clontech, Mountain View, CA, USA). Wild-type (wt) PTEN and its mutants were also cloned in pCDNA3.1 (Clontech) to be sure that GFP was not interfering with PTEN actions. Cre-recombinase was cloned in-frame into the peGFP-C1 vector (Clontech) XhoI-KpnI. All clones were confirmed by DNA sequencing and its expression by western blot. GFP-Cre-recombinase fusion protein was detected around 60 kDa. A pNFkB-SEAP vector from Clontech was used. phIGF-1luc1 ( À 1630 to þ 322) and hIGF-1LucD( þ 112 to þ 197) without the PKA regulatory region of the promoter were used as reporters of IGF-1 promoter activity (kindly provided by Peter S. Rotwein, USA).
Cell cultures
Pure astroglial cultures (495% GFAP þ , OX-42 À , A2B5 -cells) were obtained from the forebrain of postnatal day 3-4 wild-type or PTEN loxP/loxP mice (a kind gift of Tak W. Mak, Canada), as described. 52 Briefly, astroglial cultures were grown on Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. After 2 weeks, astrocytes were plated at the indicated cell densities and experiments performed. Cultures were placed in a humidified incubator at 37 1C and 5% CO 2 atmosphere. The day of the experiment, the medium was replaced by DMEM-F12 without serum. After 3 h, IGF-1 (100 nM) was added, whereas inhibitors or other drugs were given 30 min before IGF-1. Unless otherwise indicated all experiments were replicated at least three times.
Gene transfection and reporter assays
Astrocytes were seeded at 50 000 cells per well in a 12-well culture plate 24 h before transfection to reach B70% confluence. Transient transfections were performed with a total of 1.5 mg of DNA per well with Fugene 6 HD (Roche Applied Science, Basel, Switzerland) following the manufactureŕs instructions. After 48 h, medium was replaced with serum-free medium and 3 h later treated as indicated. To measure NFkB activity, 25 ml of medium was used with the SEAP reporter system (BD Biosciences) using CSPD substrate (Tropix, Life Technologies) and quantified in a luminometer (Berthold Detection Systems, Pforzheim Baden-Wü rhemberg, Germany). Transfections were normalized by cotransfection with a green fluorescent protein (peGFP-N1) expression vector. IGF-1 promoter activity was measured with the Dual Luciferase Assay kit (Promega, Fitchburg, WI, USA). Astrocytes were lysed in passive lysis buffer (PLB), and luciferase activity was analyzed using a luminometer (Berthold Detection Systems). Luciferase counts were normalized using TK-Renilla luciferase and background luminescence was subtracted. All samples were done in triplicate and independent experiments repeated at least four times.
Immunoassays
Forebrain astrocytes were seeded at 50 000 cells per well in a 12-well plate. After 24 h medium was replaced with serum-free DMEM. After 3 h, IGF-1 (100 nM) and/or TNFa (20 ng/ml) were added. Twenty-four hours later, cells were lysed in lysis buffer (50 mM Tris-HCl pH 7.4, 120 mM Cl 2 Na, 1% NP-40,1 mg/ml aprotinin, 1 mg/ml leupeptin and 1 mg/ml phenylmethylsulfonyl fluoride (PMSF)) and immunoprecipitated with an anti-N-end-PTEN antibody (1:500) and rotated overnight at 4 1C. Then, 30 ml of Protein A Sepharose 6MB (Amersham GE Healthcare, Pollards Wood, UK) was added and rotated 2 h at 41C. Astrocytes transfected with PTEN-GFP constructs were immunoprecipitated with 20 ml of agarose-conjugated anti-GFP (MBL Laboratories, Aichi, Japan). Immunoprecipitates were collected by centrifugation followed by three washes with lysis buffer. Samples were then resuspended in Laemmli buffer, subjected to SDS-polyacrylamide gel electrophoresis and transferred onto nitrocellulose membrane. Immunoprecipitated proteins were detected by western blot. The primary antibody was counterstained with a horseradish peroxidase-linked antibody and developed with the ECL system (Amersham GE Healthcare). To normalize for protein load from total lysates, membranes were reblotted (Re-Blot plus mild solution from Chemicon, Temecula, CA, USA) and incubated with an anti-b-actin antibody or the respective non phosphorylated antibody. Levels of the protein under study were expressed relative to protein load in each lane. Different exposures of each blot were collected to ensure linearity and to match control levels for quantification. Densitometric analysis was performed using Molecular Image Program (BioRad). A representative blot is shown from a total of at least three independent experiments. To detect IGF-1R phosphorylation in some experiments, astrocytes were treated with the IGF-IR inhibitor NVP -AEW541 (400 nM) for 2 h and then with 100 nM IGF-1 for 5 min. Cells were then lysed and samples were incubated with 20 ml of agarose beads conjugated with an IGF-IR antibody (Santa Cruz) overnight at 4 1C. Samples were washed four times and assayed for western blot with an antiphosphotyrosine antibody (4G10). After stripping, membranes were immunoblotted for IGF-IR. When measuring protein in culture medium, 1 ml was centrifuged, lyophylized and resuspended in 100 ml of SDS-page loading buffer. Levels of secreted protein were expressed relative to total protein in the media measured with Bradford reagent (BioRad). Rat TNFa (Diaclone, Besancon, France) and IGF-1 (R&D Systems, Minneapolis, MN, USA) ELISAs were used as described before, 52 following the manufactureŕs instructions. Absorbance was measured at 450 nM.
Enzyme activity assays
To measure the lipid phosphatase activity of PTEN, astrocytes were lysed and immunoprecipitated with the monoclonal anti-mouse PTEN antibody or agarose-conjugated anti-GFP (MBL) to separate PTEN mutant activity from endogenous PTEN. Lipid phosphatase activity was measured as described. 8 The same amount of immunoprecipitated protein was assayed by western blot to normalize PTEN phosphatase activity. PKA activity was measured as decribed 8 using the Protein Kinase A PepTag assay from Promega. After treatment, astrocytes were washed once with ice-cold PBS and lysed. Total lysates (10-25 mg in 10 ml) were incubated with the respective kinase reaction mixture (25 ml), following the manufacturer's protocol. After adding 80% glycerol (1 ml), the samples were loaded onto an agarose gel (0.8% in 50 mM Tris-HCl, pH 8.0) and run at 100 V for 15-30 min. The bands were visualized under UV light. Immediately after photographing the gel, the negatively charged phosphorylated bands were excised and heated at 95 1C until melted. The volume was adjusted to 250 ml with water. A hot agarose solution (125 ml) was added to a separate tube containing 75ml of gel solubilization solution and 50 ml of glacial acetic acid, and vortexed and transferred to a 96-well plate. PKA activity was measured by spectrofluorometry at Ex540 nm/Em590 nm.
Cell proliferation and counting
Cell proliferation was measured with a DHL Cell proliferation kit from Anaspec (Fremont, CA, USA). This fluorescence method detects cytoplasmic lactate dehydrogenase (LDH) as an indicator of cell number. Astrocyte cultures were seeded in 48-well culture plates (1 Â 10 3 cells/well). After treatment, resazurin (40 ml/well) was added and incubated for 30 min at 37 1C in the dark. Fluorescence was measured at an excitation/emission wavelength of o540/590. For cell counting, astrocytes were plated onto 24-well plates. At the indicated times, cells were gently washed with PBS, trypsinized, collected, resuspended and dyed with Trypan blue. Live cell number was determined by counting with the aid of a hemacytometer under an inverted light microscope. Cell proliferation was also studied by measuring cell confluence over time using the Incucyte 2010A Rev2 software (Essen Bioscience, Hertforshire, UK). Astrocytes were plated onto 24-well plates, and phase-contrast pictures were taken every 24 h to measure cell confluence. All experiments were done in triplicate at least three times.
Immunofluorescence
Cells were cultured on poly-D-lysine-coated glass coverslips, transfected and treated as indicated below. Cells were washed twice with PBS, fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100. Coverslips were blocked with 5% horse serum and incubated overnight at 4 1C with a GFP primary antibody in PB containing 0.1% bovine albumin, 3% horse serum and 0.2% Triton X-100. After several washes in PB, sections were incubated with an Alexa-coupled secondary antibody (1/1000). Omission of primary antibody was used as control. Analysis was performed using a Leica microscope. All pictures were taken under a Â 40 magnification.
Analysis of reactive oxygen species
To measure increases in cellular peroxide production we used MitoSOX Red mitochondrial superoxide indicator from Molecular Probes (M36008). Briefly, astrocytes were cultured on poly-D-lysine-coated glass coverslips and transfected. Seventy-two hours later, cells were washed twice with Gain-of-function of PTEN in glioma S Fernández et al PBS, incubated with 1 mM MitoSOX reagent for 10 min at 37 1C and washed with PBS. Pictures were taken under Â 40 magnification.
Colony formation assays and PTEND51 xenografts
For colony formation assays, astrocytes were nucleoporated with the mouse Astrocyte Nucleofector Kit (Amaxa, Lonza, Basel, Switzerland). Medium was replaced 24 h later. After 72 h, G418 antibiotic (1 mg/ml) was added. Four days later, all non transfected cells were dead. Medium was then replaced with 200 mg/ml of G418 and cells were allowed to grow to confluence. Fresh medium was replaced every 4-5 days. Two weeks later cells were fixed with acetic acid/methanol (1:3) for 10 min and washed three times with PBS. Cultures were stained with Crystal Violet 0.1% (C3886 Sigma) for 30 min, washed again six times with PBS and dried at room temperature. Stable transfections with pGFP-Cre were also done to delete PTEN in primary mouse Pten loxP/loxP astrocytes. More than 95% of PTEN was lost as measured by western blot. In transient transfections, around 70% of PTEN reduction was observed. To test in vivo tumor formation, SCID mice (6-10 weeks old) were subcutaneously injected with 3 Â 10 6 astrocytes stably transfected with PTEND51 or GFP. Tumor size was assessed with a manual caliper for several weeks until sacrifice.
Statistics
A Students's t-test was used to calculate differences between groups; differences were considered significant at Po0.05.
